Evidence map›Paper›PMID 32932966›Full record

ArticleGenes2020

Effect of

Thomas O Bergmeijer, Alfi Yasmina, Gerrit J A Vos, Paul W A Janssen, Christian M Hackeng, Johannes C Kelder, Shefali S Verma, Marylyn D Ritchie, Li Gong, Teri E Klein and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Personalized medicine in cardiovascular disease: review of literature.Journal of diabetes and metabolic disorders · 2021
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Thomas O BergmeijerDepartment of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.ORCID 0000-0002-7900-9926
Alfi YasminaDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.ORCID 0000-0002-2337-713X
Gerrit J A VosDepartment of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Paul W A JanssenDepartment of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Christian M HackengDepartment of Clinical Chemistry, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Johannes C KelderDepartment of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Shefali S VermaDepartment of Genetics, Center for Translational Bioinformatics, Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Marylyn D RitchieDepartment of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA.
Li GongDepartment of Biomedical Data Science and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Teri E KleinDepartment of Biomedical Data Science and Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Icpc Investigators
Anthonius de BoerDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.ORCID 0000-0002-9485-8037
Olaf H KlungelDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.
Jurriën M Ten BergDepartment of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Vera H M DeneerDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.
Utrecht University · NLSt. Antonius Ziekenhuis · NLStanford University · USUniversity of Pennsylvania · US

Funding

Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
PharmGKB: pharmacogenomics discovery and implementationU24HG010615 · NHGRI · STANFORD UNIVERSITY · PI TERI Ellen KLEIN, Michelle Whirl-Carrillo · 2020 to 2026
$9.5M
NHGRI NIH HHS U24 HG010615NIH HHS R24 GM61374NIH HHS U01 HL105198
6 · The paper itself

Abstract

This study aims to determine whether genetic variants that influence

Indexed as

Polymorphism, GeneticAgedAnticholesteremic AgentsBlood PlateletsClopidogrelCohort StudiesCoronary Artery DiseaseCytochrome P-450 CYP3AFemaleHumansMalePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPPAR alphaAnticholesteremic AgentsClopidogrelCYP3A4 protein, humanCytochrome P-450 CYP3APlatelet Aggregation InhibitorsPPAR alphaPPARA protein, humanclopidogrelCYP3A4fibrategenotypingPCIpersonalized medicinepharmacogenomicsPPARstatin

Identifiers

PMID32932966
PMCPMC7564055
OpenAlexW3085122625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.